UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update - Recently...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for...
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday...
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to...
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility...
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene...
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.